Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Sees A Path Forward For Xarelto In Post-Hospital VTE Despite MARINER Failure

Executive Summary

The company says the MARINER data combined with prior MAGELLAN results in acute medically ill patients support prophylaxis for VTE following a hospital stay in select individuals. However, there is no regulatory path forward in heart failure based on the COMMANDER HF study.

You may also be interested in...

Bayer/J&J contemplate edge of the earth in VTE as MAGELLAN scuppers Xarelto

Bayer and Johnson & Johnson's attempts the circumnavigate the world of venous thromboembolism (VTE) prevention with their oral Factor Xa inhibitor Xarelto (rivaroxaban) have hit an unexpected setback in the MAGELLAN study of medically ill patients.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

Flagship, ARCH Close VC Funds Totaling $2.56bn

Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts